Table 2.

Subject characteristics.

Controls	Age	Height	Weight	BMI	Medications	Past Diagnoses
E001	19	5’8.5”	180	27.4	None	None
E003	18	5’3”	170	30.1	None	None
E006	21	5’8”	170	25.8	None	None
E007	33	6’0”	162	22.0	Amoxicillin top	None
E008	20	5’3”	156	26.4	NuvaRing¹	None
E009	19	5’0”	135	26.4	None	None
E010	24	5’5”	128	21.3	Levora²	None
E014	26	5’8”	160	24.3	Ibuprofen	None
E023	31	5’8”	135	20.5	None	Vasovagal syncope
E024	36	5’7”	165	26.0	Birth control	None
E025	36	5’6”	140	22.1	Asthma Inhalers³	None

FMS Patients	Age	Height	Weight	BMI	Medications	Past Diagnoses	WPI/SS
E011	32	5’9”	145	21.4	Tramadol	Endometriosis	9/5
					Triamterene
					Zarah⁴
					Cyclobenzaprine
					Bupropion SR
					Trazodone prn
					Lidocaine oin prn
					Lidoderm patch prn
E012	47	5’2”	190	34.8	Duloxetine	Hypothyroid, GERD	11/9
					Acyclovir
					Levothyroxin
					Pantoprazole
E020	46	5’4”	138	23.7	Citalopram	None	7/5
E020	46	5’4”	138	23.7	Adderall⁵	None	7/5
E021	50	5’4”	130	22.3	Gabapentin	Mild Depression	5/10
E021	50	5’4”	130	22.3	Venlafaxine	(6 of 9 on PDSQ)	5/10
E027	39	5’6”	135	21.8	Duloxetine	None	17/12
					Gabapentin
					Zolpidem
E029	25	5’11”	165	23.0	Duloxetine	None	10/11
E029	25	5’11”	165	23.0	Gabapentin	None	10/11
E030	31	5’8”	205	31.2	Gabapentin	Herniated disc,	11/9
					Lisinopril	bone spurs
					Tramadol
					Bupropion
					Zolpidem
					Cyclobenzaprine
E033	43	5’2”	113	20.7	Gabapentin	osteoarthritis	5/9
E033	43	5’2”	113	20.7	Cetirizine	osteoarthritis	5/9
E035	20	5’8”	127	19.3	Gabapentin	None	9/12
E037	38	5’4.5”	170	28.3	Pregabalin	Allergies	5/11
					Mometasone spray
					Azelastine spray
					Fexofenadine
					Ibuprofen,
					Cyclobenzaprine
					Montelukast
E038	30	5’5”	170	28.3	None	None	7/6
E039	46	5’6”	175	28.2	Gabapentin	None	10/5
E039	46	5’6”	175	28.2	Amitriptyline	None	10/5
E041	37	5’5”	125	20.8	Gabapentin	None	7/5
E041	37	5’5”	125	20.8	Birth control	None	7/5

etonogestrel/ethynyl estradiol vaginal ring

levonorgestrel and ethinyl estradiol tablets

fluticasone/salmeterol and albuterol inhalers

⁴

drospirenone/ethinyl estradiol tablets

⁵

amphetamine/dextroamphetamine

Diagnostic criteria for fibromyalgia is considered to be satisfied if (1) widespread pain index (WPI)≥7 and somatic symptom severity score (SS)≥5 or if WPI 3–6 and SS≥9; (2) symptoms were present at a similar level for at least 3 months; and (3) the patient does not have a disorder that would otherwise explain the pain. WPI and SS scores defining the final patient group were determined as described in methods. Patient medical records were reviewed by a physician to confirm documentation that the latter two criteria were met. WPI/SS data for volunteers only include those patients who met the diagnostic criteria for FMS.